How can we prevent disease relapse in Graves’ orbitopathy after immunosuppressive treatment?

References

• Campi I, Vannucchi G, Salvi M. THERAPY OF ENDOCRINE DISEASE: endocrine dilemma: management of Graves’ orbitopathy. Eur J Endocrinol. 2016;175:R117–R133.
   PubMedGoogle Scholar
• Bartalena L. Graves’ orbitopathy: imperfect treatments for a rare disease. Eur Thyroid J. 2013;2:259–269.
   PubMedGoogle Scholar
• Mourits MP, Prummel MF, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clinical Endocrinol. 1997;47:9–14.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the european group on graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273–275.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Kahaly GJ, and Baldeschi L, et al. The 2021 European group on graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185:G43–G67.
   PubMed Web of Science ®Google Scholar
• Currò N, Covelli D, Vannucchi G, et al. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid. 2014;24:897–905.
   PubMed Web of Science ®Google Scholar
• Douglas RS, Kahaly GJ, and Ugradar S, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology. 2022;129:438–449.
   PubMed Web of Science ®Google Scholar
• Tanda ML, Gallo D, Ippolito S, et al. Treatment of moderate-to-severe and active Graves’ orbitopathy: a step forward from the OPTIC study. J Endocrinol Invest. 2020;43:1523–1525.
   PubMedGoogle Scholar
• Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021;9:360–372.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Marinò M, Marcocci C, et al. Teprotumumab for Graves’ orbitopathy and ototoxicity: moving problems from eyes to ears? J Endocrinol Invest. 2022;45:1455–1457.
   PubMedGoogle Scholar
• Bartalena L, Wiersinga WM. Proposal for standardization of primary and secondary outcomes in patients with active, moderate-to-severe Graves’ orbitopathy. Eur J Endocrinol. 2020;9:3–16.
   Google Scholar
• Terwee C, Wakelkamp I, Tan S, et al. Long-term effects of Graves’ ophthalmopathy on health-related quality of life. Eur J Endocrinol. 2002;146:751–757.
   PubMed Web of Science ®Google Scholar
• Ponto KA, Pitz S, Pfeiffer N, et al. Quality of life and occupational disability in endocrine orbitopathy. Dtsch Arztebl Int. 2009;106:283–289.
   PubMed Web of Science ®Google Scholar
• Salvi M, Campi I. Medical treatment of Graves’ orbitopathy. Horm Metab Res. 2015;47:779–788.
   PubMed Web of Science ®Google Scholar
• Selva D, Chen C, King G. Late reactivation of thyroid orbitopathy. Clin Exp Ophthalmol. 2004;32:46–50.
   PubMed Web of Science ®Google Scholar
• Patel P, Khandji J, Kazim M. Recurrent Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg. 2015;31(6):445–448.
   PubMed Web of Science ®Google Scholar
• Wiersinga W, Žarković M, Bartalena L, et al. Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism. Eur J Endocrinol. 2018;178:635–643.
   PubMedGoogle Scholar
• Baldeschi L, Lupetti A, Vu P, et al. Reactivation of Graves’ orbitopathy after rehabilitative orbital decompression. Ophthalmology. 2007;114:1395–1402.
   PubMed Web of Science ®Google Scholar
• Lanzolla G, Sabini E, and Leo M, et al. Statins for Graves’ orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. Lancet Diabetes Endocrinol. 2021;9:733–742.
   PubMedGoogle Scholar
• Bartalena L, Piantanida E, and Gallo D, et al. Epidemiology, natural history, risk factors, and prevention of Graves’ orbitopathy. Front Endocrinol. 2020;11:615993.
   PubMed Web of Science ®Google Scholar
• Hegediüs L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves’ ophthalmopathy. J Endocrinol Invest. 2004;27:265–271.
   PubMed Web of Science ®Google Scholar
• Rigotti NA, Kruse GR, Livingstone-Banks J, et al. Treatment of tobacco smoking: a review. JAMA. 2022;327:566–577.
   PubMedGoogle Scholar
• Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338:73–78.
   PubMed Web of Science ®Google Scholar
• Vannucchi G, Covelli D, Campi I, et al. Prevention of orbitopathy by oral or intravenous steroid prophylaxis in short duration Graves’ disease patients undergoing radioiodine ablation: a prospective randomized control trial study. Thyroid. 2019;29:1828–1833.
   PubMed Web of Science ®Google Scholar
• Lanzolla G, Marinò M, Marcocci C. Selenium in the treatment of Graves’ hyperthyroidism and eye disease. Front Endocrinol. 2021;11:608428.
   PubMedGoogle Scholar
• Zang S, Ponto KA, Kahaly GJ. Intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96:320–332.
   PubMed Web of Science ®Google Scholar
• Sobel RK, Aakalu VK, Vagefi MR, et al. Orbital radiation for thyroid eye disease: a report by the American Academy of Ophthalmology. Ophthalmology. 2022;129:450–455.
   PubMedGoogle Scholar
• Vannucchi G, Covelli D, and Campi I, et al. The therapeutic outcome to intravenous steroid therapy for active Graves’ orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor. Eur J Endocrinol. 2013;170:55–61.
   PubMedGoogle Scholar
• Bartalena L, Veronesi G, Krassas GE, et al. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest. 2017;40:547–553.
   PubMedGoogle Scholar
• Salvi M, Vannucchi G, Currò N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100:422–431.
   PubMed Web of Science ®Google Scholar
• Stan MN, Salvi M. MANAGEMENT OF ENDOCRINE DISEASE: rituximab therapy for Graves’ orbitopathy - lessons from randomized control trials. Eur J Endocrinol. 2017;176:R101–R109.
   PubMed Web of Science ®Google Scholar